| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Anti-PD-1 treatment for MSI-H/MMRD tumors. A journey from genomics to transformative patient breakthroughs
|
Argilés, G.
|
|
|
36 |
3 |
p. 231-232
|
article
|
| 2 |
Corrigendum to “Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma”
|
Kim, T.M.
|
|
|
36 |
3 |
p. 352
|
article
|
| 3 |
Corrigendum to “Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023”
|
Curigliano, G.
|
|
|
36 |
3 |
p. 351
|
article
|
| 4 |
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study
|
Zhou, L.
|
|
|
36 |
3 |
p. 331-339
|
article
|
| 5 |
Editorial Board
|
|
|
|
36 |
3 |
p. iii
|
article
|
| 6 |
ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update
|
Cherny, N.I.
|
|
|
36 |
3 |
p. 247-262
|
article
|
| 7 |
Is the abundance of B cells the best biomarker to predict immune checkpoint inhibitor response in head and neck squamous cell cancers?
|
Low, J.L.
|
|
|
36 |
3 |
p. 238-239
|
article
|
| 8 |
Letter to the Editor regarding ‘Clinical validation of a tissue-agnostic genome-wide methylome enrichment molecular residual disease assay for head and neck malignancies’ by G Liu et al.
|
Zhang, C.
|
|
|
36 |
3 |
p. 344-345
|
article
|
| 9 |
Locally advanced microsatellite instability-high esophagogastric cancer: are we ready to change our treatment paradigm?
|
Ilson, D.H.
|
|
|
36 |
3 |
p. 233-234
|
article
|
| 10 |
Long-term outcomes in the PRIMA trial: a closer look at progression-free survival and overall survival
|
Wu, T.
|
|
|
36 |
3 |
p. 340
|
article
|
| 11 |
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors
|
Di Federico, A.
|
|
|
36 |
3 |
p. 297-308
|
article
|
| 12 |
Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy
|
Martínez-Castedo, B.
|
|
|
36 |
3 |
p. 263-276
|
article
|
| 13 |
Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study
|
André, T.
|
|
|
36 |
3 |
p. 277-284
|
article
|
| 14 |
Reply to Letter to the Editor ‘Long-term outcomes in the PRIMA trial: a closer look at PFS and OS’ by Wu et al.
|
González-Martín, A.
|
|
|
36 |
3 |
p. 341-342
|
article
|
| 15 |
Reply to Letter to the Editor regarding “Clinical validation of a tissue-agnostic genome-wide methylome enrichment molecular residual disease assay for head and neck malignancies” by C. Zhang
|
Liu, G.
|
|
|
36 |
3 |
p. 345-346
|
article
|
| 16 |
Six-year duration of adjuvant imatinib in high-risk GIST: more to come
|
Blay, J.Y.
|
|
|
36 |
3 |
p. 346-347
|
article
|
| 17 |
Table of Contents
|
|
|
|
36 |
3 |
p. i-ii
|
article
|
| 18 |
Targeting the future: Antibody-Drug Conjugates (ADCs) in platinum-sensitive ovarian cancer in the post-PARP era
|
Chambers, L.M.
|
|
|
36 |
3 |
p. 244-246
|
article
|
| 19 |
The best management for most patients with incurable cancer is on a clinical trial
|
Subbiah, V.
|
|
|
36 |
3 |
p. 240-243
|
article
|
| 20 |
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial
|
Alvarez Secord, A.
|
|
|
36 |
3 |
p. 321-330
|
article
|
| 21 |
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO
|
Raimondi, A.
|
|
|
36 |
3 |
p. 285-296
|
article
|
| 22 |
Tumor and blood B-cell abundance outperforms established immune checkpoint blockade response prediction signatures in head and neck cancer
|
Chang, T.-G.
|
|
|
36 |
3 |
p. 309-320
|
article
|
| 23 |
Unravelling lung adenocarcinoma with mucinous histology and its translational implications
|
Prince, S.S.
|
|
|
36 |
3 |
p. 235-237
|
article
|
| 24 |
Updated treatment recommendations for third and further lines of treatment in advanced colorectal cancer: from the ESMO Metastatic Colorectal Cancer Living Guideline
|
Candia, L.
|
|
|
36 |
3 |
p. 342-344
|
article
|
| 25 |
VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial
|
Pistilli, B.
|
|
|
36 |
3 |
p. 348-350
|
article
|
Journal description